title: Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome.
abstract: OBJECTIVE
  to compare the effectiveness of metformin and pioglitazone in ameliorating insulin resistance and cardiovascular risk factors in women with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  this study was a randomized clinical trial to compare treatment with metformin and pioglitozone. Fifty two women with PCOS aged 20-45 years were randomly allocated to one of the two treatment groups. All patients underwent clinical and biochemical evaluation and analyses involving these measures which consisted of repeated measures MANOVA using the pre- and post-intervention fasting blood sugar (FBS), lipid profiles, body mass index (BMI), serum insulin in two groups.
  
  
  RESULTS
  weight and BMI were significantly decreased in metformin group but not in case of pioglitazone. FBS, serum triglycerides, total cholesterol were all reduced significantly by both metfomin and pioglitazone. Insulin resistance measured by homeostasis model assessment (HOMA) method was significantly decreased in both treatment groups (P<0.05). There were no significant differences between treatments in most of variables except BMI.
  
  
  CONCLUSIONS
  these results suggest pioglitazone is as effective as metformin in improving insulin sensitivity and some cardiovascular risk biomarkers but it has no significant effect on reducing BMI and body weight.
authors.affiliation: Department of Endocrinology, Metabolic Disease Research Center, Qazvin University of Medical Science, Qazvin, Iran.
authors.forename: Amir
authors.initials: A
authors.lastname: Ziaee
authors.forename: Sonia
authors.initials: S
authors.lastname: Oveisi
authors.forename: Atefeh
authors.initials: A
authors.lastname: Abedini
authors.forename: Sima
authors.initials: S
authors.lastname: Hashemipour
authors.forename: Toktam
authors.initials: T
authors.lastname: Karimzadeh
authors.forename: Azam
authors.initials: A
authors.lastname: Ghorbani
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D000077205:Pioglitazone; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D012306:Risk; D045162:Thiazolidinediones / Q000627:therapeutic use*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D045162:Thiazolidinediones; D014280:Triglycerides; D008687:Metformin; D002784:Cholesterol; D000077205:Pioglitazone